Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research
Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study
ConclusionsDulaglutide demonstrated better glycemic outcomes and lower all-cause costs per 1% HbA1c reduction among Hispanic/Latino adults compared with those initiating basal insulin. Our real-world findings in the Hispanic/Latino population were consistent with results obtained from the overall population and confirm the glycemic benefits of dulaglutide observed in clinical settings. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research
Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study
ConclusionsBoth formulations of semaglutide provided clinically and statistically significant reductions in HbA1c and weight in real-world practice. Oral GLP-1 RA may offer a practical and effective option for the management of T2D. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 1, 2024 Category: Endocrinology Source Type: research
Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
ConclusionThese results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research
Publisher Correction: Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model
(Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research
Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study
ConclusionThese results demonstrate the potential for an alternate therapy, such as CRNT supported via telemedicine, to enable maintenance of weight loss and glycemia below therapeutic targets following discontinuation of GLP-1 therapy. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research
Publisher Correction: Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model
(Source: Diabetes Therapy)
Source: Diabetes Therapy - February 29, 2024 Category: Endocrinology Source Type: research
Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
ConclusionTirzepatide is a novel agent for the treatment of diabetes and has different efficacy in Asians and non-Asians. Asians were more likely to experience weight loss and gastrointestinal adverse events, whereas non-Asians were more likely to have better glycemic control and more metabolic and nutritional disorders.Trial RegistrationPROSPERO registration no. CRD42023489588. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist
ConclusionThe observed pharmacokinetic differences due to the prandial state are unlikely to contribute to clinically meaningful differences in the efficacy of orforglipron. The safety profile was consistent with the known profiles of other GLP-1 RAs. Given the absence of prandial restrictions, orforglipron may emerge as a convenient oral treatment option for patients with type 2 diabetes or obesity.Trial RegistrationClinicalTrials.gov identifiers, NCT03929744 and NCT05110794. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis
ConclusionsThere was no statistically significant risk of cardiovascular-related events in the short or medium term in patients with diabetes who received intravitreal anti-VEGF therapy, despite a small increase in the number of CVD events. Our study supports the real-world safety of intravitreal anti-VEGF therapy in patients with diabetes free of baseline CVD. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Trends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study
ConclusionMore than half of the people with T2D belonging to obesity class I –IV or central obesity had poor glycemic control (HbA1c ≥ 7%), especially in the 18–44 age group. This highlights the need for body weight management for better glycemic control in relatively young Japanese people with T2D and obesity. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Cardiovascular Outcomes with Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Patients with Diabetes: A Real-World Data Analysis
ConclusionsThere was no statistically significant risk of cardiovascular-related events in the short or medium term in patients with diabetes who received intravitreal anti-VEGF therapy, despite a small increase in the number of CVD events. Our study supports the real-world safety of intravitreal anti-VEGF therapy in patients with diabetes free of baseline CVD. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Comparative Efficacy and Safety of Tirzepatide in Asians and Non-Asians with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
ConclusionTirzepatide is a novel agent for the treatment of diabetes and has different efficacy in Asians and non-Asians. Asians were more likely to experience weight loss and gastrointestinal adverse events, whereas non-Asians were more likely to have better glycemic control and more metabolic and nutritional disorders.Trial RegistrationPROSPERO registration no. CRD42023489588. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist
ConclusionThe observed pharmacokinetic differences due to the prandial state are unlikely to contribute to clinically meaningful differences in the efficacy of orforglipron. The safety profile was consistent with the known profiles of other GLP-1 RAs. Given the absence of prandial restrictions, orforglipron may emerge as a convenient oral treatment option for patients with type 2 diabetes or obesity.Trial RegistrationClinicalTrials.gov identifiers, NCT03929744 and NCT05110794. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
Trends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study
ConclusionMore than half of the people with T2D belonging to obesity class I –IV or central obesity had poor glycemic control (HbA1c ≥ 7%), especially in the 18–44 age group. This highlights the need for body weight management for better glycemic control in relatively young Japanese people with T2D and obesity. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 24, 2024 Category: Endocrinology Source Type: research
